# US 2023/0053409 A1 · Atac-seq data normalization and method for utilizing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053409 A1
- Document ID: US20230053409A1
- Status: Published application
- Kind: A1
- Application number: 17/791,970
- Filed: 2020-10-30
- Published: 2023-02-23
- Earliest claimed: 2020-01-09
- Assignees: Seoul National University R&Db Foundation
- Applicants: Seoul National University R&Db Foundation
- Inventors: Hang Rae KIM; Hyun Mu SHIN; Gwanghun KIM
- Web page: https://patentgrep.com/patent/US20230053409A1

## CPC

- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- C12Q 1/6851: Quantitative amplification
- C12Q 1/6869: Methods for sequencing
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 40/10: Signal processing, e.g. from mass spectrometry [MS] or from PCR
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates to ATAC-seq data normalization for utilizing epigenetic information associated with chromatin openness, and a method for utilizing same. According to the present invention, it is possible to readily normalize and quantitatively compare ATAC-seq in various samples and various cohorts, and selected differential peaks can be used in various epigenetic studies, the diagnosis of diseases, and prediction of the prognoses of diseases.

## Claims

### Claim 1

A method for selecting normalization control peak for normalization of ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing), the method comprising steps of:
a) aligning and peak calling cell-derived ATAC-seq data;
b) selecting overlapped peaks between cell samples among the peaks called in step a);
c) selecting a peak coincident with DNase I hypersensitivity consensus peak among the peaks selected in step b); and
d) selecting a peak having a coefficient of variation (CV) of less than 0.3 and peak width of less than 500 bp among the peaks selected in step c).

### Claim 2 (depends on 1)

The method of claim 1, wherein the peak selected in step c) is located at a transcription start site (TSS) or 5′ untranslational region (5′ UTR).

### Claim 3 (depends on 1)

The method of claim 1, wherein the cell is one selected from the group consisting of cancer cells, stem cells, immune cells, inflammatory cells, epithelial cells, hematopoietic cells, and fibroblasts.

### Claim 4 (depends on 1)

A normalization control peak selected by the method of claim 1.

### Claim 5 (depends on 4)

The normalization control peak of claim 4 comprising at least one selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 232.

### Claim 6 (depends on 5)

The normalization control peak of claim 5, wherein the normalization control peak includes one or more selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 20.

### Claim 7 (depends on 1)

A method for selecting ATAC-seq normalization factor (F), the method comprising steps of:
a) deriving an average height (k) of an individual normalization control peak selected from an individual sample by dividing the area of the individual normalization control peak selected by the method of claim 1 by a peak width in an individual sample in a cohort as shown in the following formula:
Average Height (k) of an Individual Peak
k
=
area
width
=
the
⁢
sum
⁢
of
⁢
enrichment
⁢
within
⁢
the
⁢
peak
the
⁢
base
⁢
length
⁢
of
⁢
peak
;
b) selecting m number of normalization control peaks existing in the individual sample in the cohort, and deriving a mean height (h), which is a mean value of the average heights (k) of the selected m number of normalization control peaks, through the following formula:
Mean Height (h) of Selected Peaks in Each Sample
h
=
∑
i
=
1
m
k
i
m
,
k
i
=
the
⁢
area
⁢
⁢
A
i
⁢
of
⁢
the
⁢
ith
⁢
peak
the
⁢
base
⁢
length
⁢
of
⁢
the
⁢
ith
⁢
peak
m=the number of selected peaks in a sample; and
c) deriving an ATAC-seq normalization factor (F) through the following formula:
F
ab
=
s
a
(
=
∑
i
=
1
n
a
h
ai
n
a
)
h
bj
⁢
for
⁢
1
≤
a
≤
b
≤
2
hai=the mean height of the ith sample in the cohort Ca
hbj=the mean height of the jth sample in the cohort Cb
na=the number of samples in the cohort Ca

### Claim 8 (depends on 7)

The method of claim 7, wherein the mean height (h) represents a degree of chromatin openness of the individual sample.

### Claim 9 (depends on 8)

The method of claim 8, wherein m, which is the number of the normalization control peaks selected in the sample, is 5 to 50.

### Claim 10 (depends on 7)

A method of normalizing the area value of a peak, wherein the method comprising multiplying the ATAC-seq normalization factor (F) selected by the method of claim 7 as in the following formula:
Normalized area(A)=Fab×Aq
wherein Fab is defined as follows:
F
ab
=
s
a
(
=
∑
i
=
1
n
a
h
ai
n
a
)
h
bj
⁢
for
⁢
1
≤
a
≤
b
≤
2
hai=the mean height of the ith simple in the cohort Ca
hbj=the mean height of the jth sample in the cohort Cb
na=the number of samples in the cohort Ca
and Aq represents an area value of the q-th peak of the j-th sample of the cohort Cb.

### Claim 11 (depends on 10)

The method of claim 10, wherein m, which is the number of the normalization control peaks selected in the sample, is 5 to 50.

### Claim 12 (depends on 9)

A method of selecting a differential peak for predicting the responsiveness of anti-PD-1 therapy, the method comprising steps of:
a) aligning and peak calling ATAC-seq data from patients who respond to anti-PD-1 therapy and those who do not;
b) selecting a peak which is distinct from the responding and non-responding patient samples from among the peak calling values of step a);
c) normalizing the selected peak area by multiplying a peak area value (Ad) of the peak selected in step b) by the ATAC-seq normalization factor (Fab) selected by the method of claim 9 as in the following formula:
Normalized area(A)=Fab×Ad;
d) selecting a peak having a normalized area value exceeding a mean area value of the normalized peak area values obtained in step c) from among the peaks selected in step b); and
e) selecting a peak in which a mean difference between normalized peak area values from among patient samples responding to and non-responding to anti-PD-1 therapy among the peaks selected in step d) satisfies significance p<0.05.

### Claim 13 (depends on 12)

The method of claim 12, wherein the peak calling of step a) is performed using two or more types of peak callers selected from the group consisting of HOMER (Hypergeometric Optimization of Motif EnRichment) suite, Model-based Analysis of ChIP-Seq 2 (MACS2), and CisGenome, and
wherein the selection of step b) is performed by selecting a commonly distinct peak from the two or more types of peak callers.

### Claim 14 (depends on 13)

A differential peak for predicting the responsiveness of anti-PD-1 therapy, which is selected by the method of claim 13.

### Claim 15 (depends on 14)

The differential peak of claim 14, wherein the differential peak selected by the method includes one or more selected from the group consisting of SEQ ID NO: 233 to SEQ ID NO: 299.

### Claim 16 (depends on 15)

The differential peak of claim 15, wherein the differential peak includes one or more selected from the group consisting of SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 237, SEQ ID NO: 249, SEQ ID NO: 252, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 267, and SEQ ID NO: 268.

### Claim 17

A biomarker composition for predicting the responsiveness of anti-PD-1 therapy, the composition comprising one or more predictive peaks selected from the group consisting of SEQ ID NO: 233 to SEQ ID NO: 299.

### Claim 18 (depends on 17)

The biomarker composition of claim 17, wherein the predictive peak includes one or more selected from the group consisting of SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 237, SEQ ID NO: 249, SEQ ID NO: 252, SEQ ID NO: 261, SEQ ID NO: 262, SEQ ID NO: 267, and SEQ ID NO: 268.

### Claim 19 (depends on 17)

The biomarker composition of claim 17, wherein the biomarker composition includes four or more of the predictive peaks.

### Claim 20 (depends on 17)

The biomarker composition of claim 17, wherein the predictive peak recognizes differences in chromatin openness between patients responding to and non-responding to anti-PD-1 therapy to provide responsiveness information to anti-PD-1 therapy.
